Need help finding statistics HR jm anyone

[fightit]

Can anyone help me find any data to show that going outside of SOC and giving larger doses of peg and riba has shown positive results. I know some doctors are doing this, but is it a study that they are in or is there some reason they feel that the increased doses are more effective. I thought when the drugs were tested they experimented with the doses to find the best/safest dose to use. If the increased amounts have been having success is there any data to support it?

[jmjm530]

Probably should add that Alinia shows a lot of promise and could be added to the mix, also a recent article on phlebotomy helping to increase odds of SVR. Another possible edge might be to pre-dose ribavirin. If I had significant liver damage and planned on re-treating, I'm sure I'd be looking at all these things and probably use a combination unless I ended up in a PI trial where protocol would be dictated. If I didn't have significant liver damage I'd probably wait until the ammo arsenal is better and better understood.

[jmjm530]

Higher doses of Pegs (double dosing for example) and higher doses of ribavirin have been used successfuly with prior non-responders. Also some success with changing the Peg to Infergen. Best to find a good liver specialist (hepatologist) who can help you weigh the risks of adding more agressive regimens to the rewards of an incremental better shot at SVR. Then there are the new PI trials as well, such as Telaprevir. Did you see the Jensen/Dieterich video. They talk about double-dosing on that video.

-- Jim

[fightit]

Thank you, I found a lot of good information. I found as a non responder the increased doses will not help me. I ran that trail now I need to look at other things. I feel like I'm in a small minority of people 20% of geno 1's that don't respond. Any advice on my options would be appreciated.

[Mr Liver]

There is a ton of data available regarding dosages. One thing to remember is the higher the dosages, the higher the dropout rate. SP or Roche would love to up the doses---they would sell more. But the dropout rate would negate any or all of increased revenue from the larger doses without really showing much added benefit overall. The goal is to find dosage levels the avg person can endure while demonstrating optimum results and at the same time achieving the highest completion rates.
Go to the usual places to find studies--PubMed, NIH, etc. Search "IFN dosage". That oughta do it.
regards,
Mr Liver

[jmjm530]

It's a combination of both studies and clinical experience, and of course, a lot has to do with your stats and whether you're treatment naive or treatment experienced. Here's a good site to hunt around. You might first check out the "Dieterich/Jensen" video presentation 'Doc Eye for the Hep Guy".  Free registration is required to use the site.

-- Jim